Benzyl-α-GalNAc

Benzyl-α-GalNAc

• CAS Number: 3554-93-6
• UNSPSC Description: Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-FU (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation[1][2][3].
• Target Antigen: Others
• Type: Reference compound
• Related Pathways: Others
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/o-glycosylation-in-1.html
• Purity: 99.95
• Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 5 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: O[C@@H]([C@H]([C@@H](CO)O1)O)[C@@H](NC(C)=O)[C@H]1OCC2=CC=CC=C2
• Molecular Weight: 311.33
• References & Citations: [1]Kalra AV, et al. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br J Cancer. 2007 Oct 8;97(7):910-8. Epub 2007 Oct 2.|[2]Fan X, et al. Protein O glycosylation regulates activation of hepatic stellate cells. Inflammation. 2013 Dec;36(6):1248-52. https://pubmed.ncbi.nlm.nih.gov/23743764/|[3]Kalra AV, et al. Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur J Cancer. 2009 Jan;45(1):164-73.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported